Probably, at least in terms of minimizing the risk of blood clots, according to a new study called ESTHER, published in February in the journal Circulation. The French researchers looked at 271 women ages 45 to 70 with deep vein blood clots and 610 women without, and correlated their risk with whether they used oral forms of hormone therapy, types delivered through the skin, or none at all.